Myeloproliferative Neoplasms News

Coffee no longer should be classified as carcinogenic to humans, according to a working group from WHO’s International Agency for Research on Cancer.

This year’s ASCO Annual Meeting featured the theme “Collective wisdom: The future of patient-centered care and research.”

CHICAGO — Extending anticoagulation beyond 3 months reduced risk for recurrent clots in patients with cancer, according to results presented at the ASCO Annual Meeting.

CHICAGO — Despite global variance in cancer drug prices, generic and patented drugs are less affordable in low-income countries, according to a pilot study presented at the ASCO Annual Meeting.

A novel scoring system appeared prognostic of outcome for patients with myelodysplastic syndrome undergoing HLA–matched or –mismatched allogeneic hematopoietic stem cell transplantation, according to the results of a validation study.

Patients with cancer who undergo chemotherapy may be at elevated risk for a new primary cancer several years later.

Findings presented at the ASH Annual Meeting and Exposition contribute to the growing body of literature that demonstrates a correlation between specific gene mutations and prognosis among patients with acute myeloid leukemia and myelodysplastic syndrome. Opinions are mixed in regard to how the evidence could impact scoring systems used to classify patients, which currently do not consider these mutations, but experts agree that the evidence promotes the development of new therapeutic agents.

Previous investigations conducted by the founders of the linear no-threshold model with respect to genetic effects and carcinogenesis represent “one of the greatest misapprehensions and oversight failures within the scientific research community,” according to authors of a study review published in American Journal of Clinical Oncology.

The skyrocketing cost of cancer care has come under intense criticism from patients and health care providers.

A single standard CT scan may increase the risk for fatal cancer in one of every 2,000 patients, according to FDA data.